Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma

A. Karolina Palucka, Madhav V. Dhodapkar, Sophie Paczesny, Susan Burkeholder, Knut M. Wittkowski, Ralph M. Steinman, Joseph Fay, Jacques Banchereau

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

There is evidence that dendritic cell (DC) vaccines induce tumor-specific immune responses that correlate with clinical responses. Little is known, however, about the kinetics of T-cell responses to antigens presented on DC vaccines. The authors vaccinated 18 HLA A*0201+ patients with stage IV melanoma with CD34 HPC-derived DCs pulsed with six antigens: influenza matrix peptide (Flu-MP), KLH, and peptides derived from the four melanoma antigens: MART-1/Melan A, gp100, tyrosinase, and MAGE-3. A single DC vaccination was sufficient for induction of KLH-specific CD4 T-cell responses in five patients and Flu-MP-specific CD8 T-cell responses in eight patients. A single DC vaccine was sufficient for induction of tumor-specific effectors to at least one melanoma antigen in five patients. Thus, a single injection of CD34 HPC-derived DCs can lead to rapid immune response to CD4 epitopes or to melanoma antigens.

Original languageEnglish (US)
Pages (from-to)432-439
Number of pages8
JournalJournal of Immunotherapy
Volume26
Issue number5
DOIs
StatePublished - Sep 2003
Externally publishedYes

Fingerprint

Melanoma-Specific Antigens
Dendritic Cells
Immunity
Melanoma
Vaccines
T-Lymphocytes
Injections
MART-1 Antigen
Antigens
Peptides
Cancer Vaccines
Monophenol Monooxygenase
Human Influenza
Epitopes
Vaccination
Neoplasms

Keywords

  • Cancer
  • Dendritic cells
  • Immunotherapy
  • Tumor immunology
  • Vaccine

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Immunology

Cite this

Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. / Palucka, A. Karolina; Dhodapkar, Madhav V.; Paczesny, Sophie; Burkeholder, Susan; Wittkowski, Knut M.; Steinman, Ralph M.; Fay, Joseph; Banchereau, Jacques.

In: Journal of Immunotherapy, Vol. 26, No. 5, 09.2003, p. 432-439.

Research output: Contribution to journalArticle

Palucka, A. Karolina ; Dhodapkar, Madhav V. ; Paczesny, Sophie ; Burkeholder, Susan ; Wittkowski, Knut M. ; Steinman, Ralph M. ; Fay, Joseph ; Banchereau, Jacques. / Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. In: Journal of Immunotherapy. 2003 ; Vol. 26, No. 5. pp. 432-439.
@article{52fdc40cf3ee465b8801cc941a409bab,
title = "Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma",
abstract = "There is evidence that dendritic cell (DC) vaccines induce tumor-specific immune responses that correlate with clinical responses. Little is known, however, about the kinetics of T-cell responses to antigens presented on DC vaccines. The authors vaccinated 18 HLA A*0201+ patients with stage IV melanoma with CD34 HPC-derived DCs pulsed with six antigens: influenza matrix peptide (Flu-MP), KLH, and peptides derived from the four melanoma antigens: MART-1/Melan A, gp100, tyrosinase, and MAGE-3. A single DC vaccination was sufficient for induction of KLH-specific CD4 T-cell responses in five patients and Flu-MP-specific CD8 T-cell responses in eight patients. A single DC vaccine was sufficient for induction of tumor-specific effectors to at least one melanoma antigen in five patients. Thus, a single injection of CD34 HPC-derived DCs can lead to rapid immune response to CD4 epitopes or to melanoma antigens.",
keywords = "Cancer, Dendritic cells, Immunotherapy, Tumor immunology, Vaccine",
author = "Palucka, {A. Karolina} and Dhodapkar, {Madhav V.} and Sophie Paczesny and Susan Burkeholder and Wittkowski, {Knut M.} and Steinman, {Ralph M.} and Joseph Fay and Jacques Banchereau",
year = "2003",
month = "9",
doi = "10.1097/00002371-200309000-00006",
language = "English (US)",
volume = "26",
pages = "432--439",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma

AU - Palucka, A. Karolina

AU - Dhodapkar, Madhav V.

AU - Paczesny, Sophie

AU - Burkeholder, Susan

AU - Wittkowski, Knut M.

AU - Steinman, Ralph M.

AU - Fay, Joseph

AU - Banchereau, Jacques

PY - 2003/9

Y1 - 2003/9

N2 - There is evidence that dendritic cell (DC) vaccines induce tumor-specific immune responses that correlate with clinical responses. Little is known, however, about the kinetics of T-cell responses to antigens presented on DC vaccines. The authors vaccinated 18 HLA A*0201+ patients with stage IV melanoma with CD34 HPC-derived DCs pulsed with six antigens: influenza matrix peptide (Flu-MP), KLH, and peptides derived from the four melanoma antigens: MART-1/Melan A, gp100, tyrosinase, and MAGE-3. A single DC vaccination was sufficient for induction of KLH-specific CD4 T-cell responses in five patients and Flu-MP-specific CD8 T-cell responses in eight patients. A single DC vaccine was sufficient for induction of tumor-specific effectors to at least one melanoma antigen in five patients. Thus, a single injection of CD34 HPC-derived DCs can lead to rapid immune response to CD4 epitopes or to melanoma antigens.

AB - There is evidence that dendritic cell (DC) vaccines induce tumor-specific immune responses that correlate with clinical responses. Little is known, however, about the kinetics of T-cell responses to antigens presented on DC vaccines. The authors vaccinated 18 HLA A*0201+ patients with stage IV melanoma with CD34 HPC-derived DCs pulsed with six antigens: influenza matrix peptide (Flu-MP), KLH, and peptides derived from the four melanoma antigens: MART-1/Melan A, gp100, tyrosinase, and MAGE-3. A single DC vaccination was sufficient for induction of KLH-specific CD4 T-cell responses in five patients and Flu-MP-specific CD8 T-cell responses in eight patients. A single DC vaccine was sufficient for induction of tumor-specific effectors to at least one melanoma antigen in five patients. Thus, a single injection of CD34 HPC-derived DCs can lead to rapid immune response to CD4 epitopes or to melanoma antigens.

KW - Cancer

KW - Dendritic cells

KW - Immunotherapy

KW - Tumor immunology

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0141818346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141818346&partnerID=8YFLogxK

U2 - 10.1097/00002371-200309000-00006

DO - 10.1097/00002371-200309000-00006

M3 - Article

C2 - 12973032

AN - SCOPUS:0141818346

VL - 26

SP - 432

EP - 439

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 5

ER -